Regulatory Affairs Management – EU & UK Medicinal Products

Regulatory affairs management is the discipline of ensuring that pharmaceutical products meet all legal and scientific requirements for approval and remain in compliance throughout their lifecycle. It covers regulatory strategy, marketing authorisation applications, agency liaison, and post-approval maintenance such as variations and renewals. Every medicinal product must hold a valid marketing authorisation before it can be placed on the market for sale and supply, which makes regulatory affairs management essential for lawful market access and patient safety.

ngaging a regulatory affairs consultant as early as possible is generally the most effective approach. Before initiating the marketing authorisation application process, experienced regulatory experts familiar with the EU and UK regulatory frameworks can provide guidance on requirements, identify potential challenges, and help shape the development plan accordingly. A consultant can also add value at later stages — for example, resolving a stalled submission or managing a specific lifecycle change — but early involvement helps prevent costly missteps in study design, data requirements, or pathway selection.

These are three distinct pathways to obtaining marketing authorisations across Europe, and selecting the right one is a core part of regulatory strategy. In the Centralised Procedure, a single application is assessed by the European Medicines Agency and, if approved, results in one EU-wide authorisation valid in all EU member states. The Mutual Recognition Procedure (MRP) is used when a product already holds a national authorisation in at least one member state and the MAH wishes to extend it to other member states, which then mutually recognise the original authorisation. The Decentralised Procedure (DCP) is used when the product does not yet have any national authorisation but the applicant seeks approval in multiple member states simultaneously, with one acting as the Reference Member State to lead the assessment.

Yes. Following the UK’s withdrawal from the EU, separate regulatory processes now apply to the EU/EEA and the UK. A European marketing authorisation no longer covers Great Britain (England, Scotland, and Wales), so a separate UK marketing authorisation from the MHRA is required to market a medicine there. Northern Ireland arrangements differ due to the Windsor Framework, and the specific implications for your product should be confirmed with your regulatory adviser.

Not directly. To submit a marketing authorisation application in the EU/EEA, the applicant needs to have a registered company established in the region. A non-EU company will therefore need to set up a local subsidiary or appoint an EEA-based entity to act as the MAH. Even if certain MAH activities are outsourced to that entity, the overall responsibility for the product’s quality, safety, and efficacy cannot be delegated. Regulatory consultancies can assist non-EU companies in navigating this establishment process and fulfilling local requirements.

eCTD stands for electronic Common Technical Document — a standardised digital format for compiling and submitting a medicine’s regulatory dossier to agencies such as the EMA or MHRA. Instead of paper-based submissions, all application content (from administrative data and quality information to clinical trial reports) is structured into an organised electronic format that allows agencies to review it efficiently. Pharmafile uses the advanced submission management system docuBridge for eCTD compilation and lifecycle management across National and European (CP, DCP, MRP) procedures, including renewals and variations.

For the EU Centralised Procedure, the formal assessment takes up to 210 active days of evaluation by EMA experts. This active time is interrupted by one or two “clock-stop” periods during which the applicant prepares answers to the agency’s questions — the first clock-stop usually lasts three months and the second one month. Overall, the assessment of a new medicine usually lasts around a year. In certain cases, the EMA may grant accelerated assessment, which can shorten the active review to 150 days for medicines considered of major public health interest.

The MAH is legally accountable for the quality, safety, and efficacy of the medicinal product throughout its entire lifecycle and has responsibilities under Good Manufacturing Practice (GMP), Good Distribution Practice (GDP), and Good Pharmacovigilance Practice (GVP). Key post-approval obligations include maintaining an effective pharmacovigilance system, fulfilling post-marketing commitments such as Periodic Safety Update Reports (PSURs) and Risk Management Plans (RMPs), and submitting regulatory variations for any changes to the approved product. A national marketing authorisation is initially valid for five years, after which a renewal must be submitted to confirm that the benefit/risk balance remains favourable. In practice, the MAH must also ensure that labelling, packaging, and patient information remain current and that any post-approval commitments imposed by the regulator are completed on time.

A variation is a formal regulatory submission to update or change an existing marketing authorisation. Variations are changes made to the dossier of an authorised medicinal product after its initial registration, and they may concern administrative, quality, safety/efficacy, or vigilance changes. In the EU, variations are classified as Type IA (minor, minimal or no impact on quality, safety, or efficacy), Type IB (a variation that is neither Type IA nor Type II), or Type II (major variations that may have a significant impact). Procedures around variations are governed by Commission Regulation (EC) No 1234/2008. In practical terms, almost any significant change to an approved medicine — whether to its manufacturing, formulation, labelling, or safety information — will require a variation submission to stay in compliance.

Yes. A specialist consultancy can be engaged to handle as much of the regulatory workload as needed, from strategy development and dossier preparation to submission management and post-approval lifecycle activities. Services can be tailored to meet specific needs — whether that means undertaking your whole regulatory requirements or performing any specific task where your company may have a temporary lack of resource due to increased workload or vacancies. However, even when regulatory work is outsourced, the MAH’s overall legal responsibility for the product cannot be delegated, so maintaining appropriate oversight of outsourced activities is essential.

Inspectors expect the MAH to demonstrate robust systems ensuring full compliance with all regulations and with the specific terms of the product’s authorisation. The MAH has responsibilities under GMP, GDP, and GVP, and is obliged to meet these requirements including maintaining the marketing authorisation and informing the relevant authorities when needed — for example, regarding safety information. If you use external service providers, you must show that you actively govern those activities: while MAH activities may be outsourced, the overall responsibility cannot be delegated. In practice, inspectors will look for documented evidence that every change to the product was submitted and approved as a variation, that your pharmacovigilance system is functioning, and that manufacturing and distribution remain consistent with the approved dossier.

Pharmafile has successfully managed regulatory projects across the majority of therapeutic areas and the full range of dosage forms, including capsules, tablets, injection, infusion, topical preparations, and eye drops. Product categories include prescription only medicines (POM), pharmacy (P), general sale (GSL), herbal products, food supplements, over-the-counter (OTC) products, and CE-marked products. In total, Pharmafile has achieved more than 1,000 product approvals through National, MR, and DC procedures across Europe, drawing on 30 years of experience in the pharmaceutical industry.

Yes. A core element of regulatory affairs management is acting as your liaison with competent authorities. Pharmafile’s associates have extensive experience in pre-submission preparation, submission, and lifecycle management of EU Marketing Authorisations, handling the full technical and regulatory interface with agencies on behalf of clients. This includes preparing and submitting dossiers (via eCTD using docuBridge), responding to agency questions, and managing all procedural correspondence across National and European (CP, DCP, MRP) procedures. Your company remains the official applicant or MAH, while the consultancy manages day-to-day regulatory interactions.

A regulatory affairs consultant helps reduce time to market by designing a practical regulatory strategy linked into development plans according to individual client needs. This includes advising on the most efficient approval route, performing benefit/risk analysis of regulatory options, and ensuring the dossier is complete and submission-ready to avoid validation failures or agency objections. Additionally, by managing the submission process and all communications with regulators proactively, a consultant helps prevent the delays that commonly arise from incomplete applications, misclassified variations, or late responses to agency questions.

These categories classify post-approval changes to a marketing authorisation by their level of impact. A Type IA variation is a minor change with only minimal or no impact on the quality, safety, or efficacy of the product — as defined in Commission Regulation (EC) No 1234/2008, these follow a “Do and Tell” procedure where the change can be implemented and the authority notified afterwards (either immediately for Type IAIN, or within 12 months for standard Type IA). A Type IB variation is one that is neither a minor variation of Type IA nor a major variation of Type II; it follows a “Tell, Wait, and Do” procedure with a typical 30–60 day review timetable, and the change must not be implemented until approval is received. A Type II variation is a major change — such as adding a new therapeutic indication or making significant formulation changes — requiring a comprehensive review with a timetable of 30/60/90 days (excluding clock-stops), and formal approval must be obtained before implementation.